Nemera & Biomm partner to Commercialize Reusable Insulin Pen in Brazil

Nemera’s advapen to treat diabetic patients

Nemera's Lifepen to treat diabetic patients in Brazil
Nemera's Lifepen to treat diabetic patients in Brazil

A pioneer in biotechnological medicines in Brazil, Biomm is launching Nemera’s Advapen under the trade name Lifepen to administer Glargilin insulin for the treatment of diabetes. Glargilin is a long-acting insulin analog glargine, which showed significantly less risk of hypoglycemia compared to NPH insulin, both in symptomatic and nocturnal episodes.

Around 16.8 million people have diabetes in Brazil, making it the fifth-largest country in the world after China, India, the United States of America, and Pakistan in this regard.

Nemera & Biomm collaboration has improved the health of diabetic patients

“We are convinced that the launch of lifepen will help provide improved health and more quality of life to patients with chronic conditions such as diabetes. Providing a state-of-the-art pen injector with high ergonomics and reliability is extremely important to ensure high patient compliance, which translates into the effectiveness of the treatment of diabetes. Due to its dynamic increase, diabetes is already called the epidemic of the 21st century. With the addition of Lifepen, we strengthen our existing product portfolio even more,” said Paulo Vidigal, Head of Business Development at Biomm.

“The collaboration with Biomm starting from the registration to the filing followed by the approval from Anvisa in just over a year is an incredible achievement for both companies. We are glad that our reusable pen injector Advapen is being launched in the Brazilian market where high unmet medical needs when it comes to diabetes are being addressed,” added Aurélie Oudet-Thebaud, Sales Director International Markets at Nemera.

“This product platform offers ergonomic and market-proven spring-assisted reusable pen injectors that are fully customizable, require low force of injection and are equipped for automatic delivery of medication, thus ensuring constant dosing rate,” said Dr Radoslaw Romanzcuk, Pen Platform Business Development Director at Nemera.

“At Nemera, we design and manufacture devices that maximize treatment efficacy and partner with our customers in the best possible way to ultimately bring high-quality and safe treatment solutions to patients. Our partnership with Biomm further strengthens our commitment to bringing superior value to customers and patients,” he added.



Please enter your comment!
Please enter your name here